These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15876271)

  • 1. Cost of severe haemophilia in Toronto.
    Heemstra HE; Zwaan T; Hemels M; Feldman BM; Blanchette V; Kern M; Einarson TR
    Haemophilia; 2005 May; 11(3):254-60. PubMed ID: 15876271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
    Globe DR; Curtis RG; Koerper MA;
    Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A.
    Kern M; Blanchette V; Stain AM; Einarson TR; Feldman BM
    J Pediatr; 2004 Nov; 145(5):628-34. PubMed ID: 15520762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.
    Chang H; Sher GD; Blanchette VS; Teitel JM
    Haemophilia; 1999 Jul; 5(4):247-52. PubMed ID: 10469178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost of health care in children with haemophilia].
    González-Figueroa M; Canales-Muñoz JL; Aguayo-Alcaraz G; Zamora-Vázquez G
    Rev Med Inst Mex Seguro Soc; 2010; 48(2):199-204. PubMed ID: 20929625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization among haemophilia A patients in the United States.
    Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
    Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of haemophilia treatment: a cross-national assessment.
    Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
    Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].
    Berger K; Schopohl D; Eheberg D; Oldenburg J; Tiede A; Schramm W
    Hamostaseologie; 2014; 34(4):291-300. PubMed ID: 25370177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic use of factor VIII: an economic evaluation.
    Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
    Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and utilization of treatment in patients with hemophilia.
    Rocha P; Carvalho M; Lopes M; Araújo F
    BMC Health Serv Res; 2015 Oct; 15():484. PubMed ID: 26502954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financing the rising cost of haemophilia care at a large comprehensive care centre.
    Miners AH; Sabin CA; Stevens AJ; Tolley KH; Lee CA
    J R Coll Physicians Lond; 1997; 31(6):640-4. PubMed ID: 9409497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic impact of factor VIII inhibitors in patients with haemophilia.
    Bohn RL; Aledort LM; Putnam KG; Ewenstein BM; Mogun H; Avorn J
    Haemophilia; 2004 Jan; 10(1):63-8. PubMed ID: 14962222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study.
    Carneiro JDA; Blanchette V; Ozelo MC; Antunes SV; Villaca PR; Young NL; Castro D; Brandão LR; Carcao M; Abad A; Feldman BM;
    Haemophilia; 2017 Sep; 23(5):682-688. PubMed ID: 28440005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group.
    Szucs TD; Offner A; Kroner B; Giangrande P; Berntorp E; Schramm W
    Haemophilia; 1998 Jul; 4(4):498-501. PubMed ID: 9873781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
    Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
    Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A.
    Globe DR; Cunningham WE; Andersen R; Dietrich SL; Curtis RG; Parish KL; Miller RT; Sanders NL; Kominski G;
    Haemophilia; 2003 May; 9(3):325-31. PubMed ID: 12694525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.
    Berger K; Schopohl D; Eheberg D; Auerswald G; Kurnik K; Schramm W
    Klin Padiatr; 2013 May; 225(3):152-8. PubMed ID: 23519749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.